纳米羟基磷灰石载药体治疗慢性骨髓炎的安全性实验研究

The safe empirical study about nano-HA used as antibiotic bearer in the treatment of chronic osteomyelitis

目的通过动物实验证明纳米羟基磷灰石作为抗生素载药体的生物安全性。方法 20只新西兰大白兔通过葡萄球菌接种,经4周时间演变成为慢性股骨骨髓炎模型,随机分为2组,每组10只。实验组病灶植入万古霉素纳米羟基磷灰石;对照组植入单纯纳米羟基磷灰石;分别于术后24小时、1周、2周和4周测量静脉血尿素氮及转氨酶浓度,同时取病灶局部病理检查进行分析比较。结果两组动物术后各时间点血尿素氮及转氨酶浓度对比均有>0.05,两组数据资料差异无统计学意义。实验组动物生物相容性观察,无炎症反应、异物反应。同时可见断端界面软骨内骨化形式成骨活跃。结论纳米羟基磷灰石作为抗生素载药体有着可靠的生物安全性,值得进一步深入研究。

Objective Study the safety ofnano-HA-bearer which can be degraded through Animal-model-empirical study. Methods Staphylococcus vaccination in 20 albino rabbits were developed into chronic osteomyelitis in femur, and be divide into 2 groups in radom. A-unit： vancocin-nano-HA plated into the focus of infection, B-unit： only nano-HA plated into the focus of infection. Survey the level of Blood urea nitrogen and transaminase in the two units in the postopration. In the same time observe the pathobiologic slices of the focus of infection. Results The data of the two groups is not statistically significant. No inflammatory reaction and foreign body reaction had been found in the pathobiologic slices of the focus of infection. Conclusions Nano-HA is safe when it used as antibiotic bearer in the treatment of chronic osteomyelitis.